Price
143.9
+0%52W Range
Market Cap
₹121.01 Cr
Traded: ₹0.01 Cr (0.00%) 0.0x
Free Float: ₹39.10 Cr (0.02% of FF traded)
Volume · 60D trend
416 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| Sales | -- | -6.0% | +0.0% | -- | -23.0% | Stable |
| ROE | -- | -- | -- | -- | -- | -- |
| Return | +37.0% | +150.0% | +275.0% | -- | -- | Accelerating |
| Profit | -- | -- | -13.0% | -- | -500.0% | Decelerating |
Quarterly Results
Mar 2015
Dec 2014
Sep 2014
Jun 2014
Mar 2014
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2019PDF ↗ | Mar 2019PDF ↗ | Dec 2018PDF ↗ | Sep 2018PDF ↗ | Jun 2018PDF ↗ | Mar 2018PDF ↗ | Sep 2015PDF ↗ | Jun 2015PDF ↗ | Mar 2015 | Dec 2014 | Sep 2014 | Jun 2014 | Mar 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1 | 4 | 4 | 7 | 10 | 14 | 6 | 4 | 2 | 4 | 2 | 3 | 0 |
| Expenses | 1 | 3 | 4 | 7 | 10 | 14 | 6 | 4 | 2 | 4 | 2 | 3 | 2 |
| Operating Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | -2 |
| OPM % | 0.0% | 5.8% | 2.1% | 1.4% | 0.8% | 1.4% | 3.5% | 4.5% | 25.9% | 1.6% | 1.0% | 3.0% | -1413.3% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Profit Before Tax | -0 | -0 | -0 | -0 | 0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | -2 |
| Tax % | 0.0% | 100.0% | 0.0% | 0.0% | 33.3% | -100.0% | 30.8% | 27.3% | -200.0% | 25.0% | -- | 40.0% | -29.8% |
| Net Profit | -0 | -0 | -0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2 |
| Exceptional Items | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| EPS (Rs) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -0.1 |
| Sales Growth (YoY) | -89.0% | -74.0% | -- | -- | -- | -- | 217.0% | 49.0% | 1393.0% | -55.0% | -84.0% | -80.0% | -99.0% |
| Sales Growth (QoQ) | -69.3% | -14.0% | -43.3% | -28.9% | -24.4% | 121.0% | 40.9% | 97.8% | -42.1% | 96.5% | -33.7% | 1880.0% | -- |
| OP Growth (YoY) | -100.0% | 5.0% | -- | -- | -- | -- | 1000.0% | 122.2% | 127.4% | -- | -- | -- | -- |
| OP Growth (QoQ) | -100.0% | 133.3% | -10.0% | 25.0% | -60.0% | -- | 10.0% | -65.5% | 866.7% | 200.0% | -77.8% | 104.2% | -- |
| Profit Growth (YoY) | -400.0% | -- | -- | -- | -- | -- | -- | 100.0% | 104.0% | -94.0% | -100.0% | -92.0% | -211.0% |
| EPS Growth (YoY) | -- | -- | -- | -- | -- | -- | -- | -- | 100.0% | -- | -- | -- | -- |
| EPS Growth (QoQ) | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 100.0% | -- |
| OP Margin | 0.0% | 5.8% | 2.1% | 1.4% | 0.8% | 1.4% | 3.5% | 4.5% | 25.9% | 1.6% | 1.0% | 3.0% | -1413.3% |
| Net Margin | -5.4% | -0.8% | -0.2% | -0.4% | 0.2% | 0.0% | 1.4% | 1.8% | 2.7% | 0.8% | 0.0% | 1.4% | -1006.7% |
| Material Cost % | 99.0% | 92.0% | 0.0% | 153.0% | 99.0% | 97.0% | 90.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Employee Cost % | 1.0% | 1.0% | 0.0% | 0.0% | 0.0% | 1.0% | 0.0% | 4.0% | 0.0% | 0.0% | 0.0% | 4.0% | 0.0% |
| P/S | 7.40 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 252.10 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50We hereby submit the monitoring Agency Report for utilization of proceeds of Rights Issue of iSERA Lifesciences Limited (Formerly known as Covidh Technologies Limited) for the quarter ended ....
We are hereby submitting the Unaudited Financial Results of the Company for the quarter ended June 30, 2026.
Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, the Board of Directors of the Company at its meeting held on ....
We are hereby submitting the Certificate issued by Share Transfer Agent of the Company, confirming compliance with Regulation 74(5) of SEBI (Depositories and Participants) Regulations, ....
Scrutinizer's Report and Voting Results of the Re-opened Postal Ballot (Remote E-Voting) conducted pursuant to the Corrigendum to the Postal Ballot Notice dated June 26, 2026.
Submission of Newspaper Advertisement of Corrigendum to the Postal Ballot Notice pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
We wish to inform you that iSERA Lifesciences Limited (Formerly known as Covidh Technologies Limited) has issued a Corrigendum to the Notice of Postal Ballot dated April 21, 2026, vide Corrigendum ....
We are hereby submitting the Closure of Trading Window for the Quarter June 30, 2026.
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that a meeting of the Board of Directors of iSERA Lifesciences ....
We hereby submit the Newspaper Advertisement for the financial result for the year and quarter ended March 31, 2026
We are hereby submitting the Scrutinizer''s Report for the postal ballot.
We hereby submit the declaration w.r.t. non applicability of regulation 23(9) of SEBI LODR
We hereby submitted Pursuant to the provisions of Regulation 30 and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, the Board of Directors ....
We hereby Submitted the Financial Result for the Financial Year ended 31 March 2026
Revised outcome of the board meeting for discussing and approving the financial results for the year ended 31.03.2026
Covidh Technologies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/05/2026 ,inter alia, to consider and approve the Audited Financial Results ....
Monitoring Agency Report for utilization of proceeds of Rights Issue of iSERA Lifesciences Limited (Formerly known as Covidh Technologies Limited) for the quarter ended 31, March 2026.
iSERA Lifesciences Limited (Formerly known as Covidh Technologies Limited)has filed with exchange monitoring agency report for quarter ended March 31, 2026.
Submission of Newspaper Advertisement of Postal Ballot Notice pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Pursuant to the resolution passed by the Board of Directors of the Company at its meeting held on Tuesday, April 21, 2026, the Company encloses herewith the Postal Ballot Notice dated April ....
Revised Outcome of the Meeting of the Board of Directors of iSERA Lifesciences Limited (Formerly known as Covidh Technologies Limited) ('the Company') pursuant to Regulation 29 and 30 of ....
The Board of Directors considered and approved the increase in the Authorised Share Capital of the Company from Rs. 11,00,00,000/- (Rupees Eleven Crore Only) divided into 1,10,00,000 (One ....
The Board of Directors considered and approved the acquisition of equity shares representing up to 100% of the paid-up equity share capital of iSERA Biological Limited (an unlisted public ....
ISSUANCE OF EQUITY SHARES BY WAY OF PREFERENTIAL ISSUE ON PRIVATE PLACEMENT BASIS FOR CONSIDERATION OTHER THAN CASH (SHARE SWAP)
Pursuant to our prior intimation dated April 15, 2026 and deferment intimation dated April 20, 2026, and in terms of Regulation 30 of the Securities and Exchange Board of India (Listing ....
Pursuant to our prior intimation dated April 15, 2026 and deferment intimation dated April 20, 2026, and in terms of Regulation 30 of the Securities and Exchange Board of India (Listing ....
This is with reference to our prior intimation dated April 15, 2026, regarding the meeting of the Board of Directors of iSERA Lifesciences Limited (Formerly known as Covidh Technologies ....
Covidh Technologies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/04/2026 ,inter alia, to consider and approve Pursuant to Regulation ....
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") and further to our intimation ....
I hereby submit the Certificate under Regulation 74(5) of SEBI (Depository and Participants) Regulations, 2018, for the quarter and Financial Year ended 31st March 2026
We wish to inform that the 01st Extra-Ordinary General Meeting ("EGM") of the Company was held on Thursday, April 02, 2026 at 12:00 P.M. (IST), through Video Conferencing ("VC") / Other ....
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations,2015 , we hereby submit the proceedings of the 01st Extra-Ordinary General Meeting ('EGM') ....
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit the proceedings of the 01st Extra-Ordinary General Meeting ('EGM') ....
We are hereby submitting the Closure of Trading Window for the Quarter and Financial Year ending March 31, 2026.
Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith copies of the newspaper advertisement published ....
Extra-Ordinary General Meeting (hereinafter referred to as 'EGM') of the Members of Covidh Technologies Limited will be held on Thursday, 2nd day of April, 2026 at 12:00 P.M., through ....
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Meeting of the Board of Directors of the Company ....
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Meeting of the Board of Directors of the Company ....
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Meeting of the Board of Directors of the Company ....
The Board of Directors has considered and approved, inter-alia, the shifting of the Registered Office of the Company.
Revision in Outcome of Board Meeting - Shifting of Registered Office
This is with reference to the disclosure submitted by the Company on February 23, 2026 under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ....
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI LODR Regulations'), as amended from time to time, this is to inform that ....
Pursuant to Regulation 30 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that consequent to receipt ....
Report of the Monitoring Agency with respect to utilization of proceeds of Rights Issue of Covidh Technologies Limited for the quarter ended December 31, 2025
We are hereby submitting the Intimation for Newspaper Publication of Un-Audited Financial Results for the quarter and Nine Months ending 31st December, 2025, pursuant to Regulation 47 of ....
We are hereby submitting the un-audited financial results for quarter and nine months ended 31.12.2025.
Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, the Board of Directors of the Company at its meeting held on ....
We are hereby informing that we have received the order from the Regional Director approving the shifting of the Registered Office from Hyderabad in the State of Telangana to Pune in the ....
Please find attached update on the shifting of the registered office of the Company.